Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
New Building at Rockford, Illinois site will significantly increase equipment and capacity for injectable biologics and other self-administered therapies
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Dr. Jain is a biotechnology industry veteran with more than two decades of experience in pharmaceutical development across her time with ChemoCentryx, AbbVie, Abbott Laboratories, and G.D. Searle and Co
LG Chem will receive totaling up to $95.5 million for the China rights
Subscribe To Our Newsletter & Stay Updated
